Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO – Get Free Report) insider David P. Hochman purchased 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 14th. The stock was bought at an average price of $5.84 per share, with a total value of $14,600.00. Following the transaction, the insider now owns 567,998 shares of the company’s stock, valued at approximately $3,317,108.32. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Orchestra BioMed Trading Up 5.9 %
OBIO opened at $6.42 on Friday. Orchestra BioMed Holdings, Inc. has a 12 month low of $4.22 and a 12 month high of $11.69. The stock has a 50-day moving average of $7.34 and a 200 day moving average of $6.29. The firm has a market cap of $229.76 million, a P/E ratio of -4.34 and a beta of 0.45.
Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.04). Orchestra BioMed had a negative net margin of 2,330.46% and a negative return on equity of 70.18%. The business had revenue of $0.78 million for the quarter, compared to analysts’ expectations of $1.04 million. On average, research analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.56 earnings per share for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Report on Orchestra BioMed
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the business. Bank of New York Mellon Corp boosted its position in shares of Orchestra BioMed by 115.7% during the second quarter. Bank of New York Mellon Corp now owns 70,682 shares of the company’s stock valued at $576,000 after buying an additional 37,906 shares during the period. The Manufacturers Life Insurance Company boosted its position in shares of Orchestra BioMed by 8.4% during the second quarter. The Manufacturers Life Insurance Company now owns 42,082 shares of the company’s stock valued at $343,000 after buying an additional 3,245 shares during the period. Rhumbline Advisers boosted its position in shares of Orchestra BioMed by 192.7% during the second quarter. Rhumbline Advisers now owns 26,439 shares of the company’s stock valued at $215,000 after buying an additional 17,405 shares during the period. Catalytic Wealth RIA LLC purchased a new position in shares of Orchestra BioMed during the first quarter valued at approximately $117,000. Finally, SkyView Investment Advisors LLC purchased a new stake in shares of Orchestra BioMed in the second quarter valued at approximately $163,000. Hedge funds and other institutional investors own 53.55% of the company’s stock.
About Orchestra BioMed
Orchestra BioMed Holdings, Inc operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease.
Featured Articles
- Five stocks we like better than Orchestra BioMed
- What Are Some of the Best Large-Cap Stocks to Buy?
- Bumble’s Valuation Hits an All-Time Low, Can Its Fortunes Change?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 8/12 – 8/16
- Which Wall Street Analysts are the Most Accurate?
- JD.com Earnings Surprise: China’s Outlook Better Than Expected
Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.